INVO Fertility, Inc (NASDAQ:IVF) Short Interest Up 762.2% in January

INVO Fertility, Inc (NASDAQ:IVF) saw a large increase in short interest in the month of January. As of January 30th, there was short interest totaling 354,428 shares, an increase of 762.2% from the January 15th total of 41,109 shares. Currently, 15.0% of the company’s shares are sold short. Based on an average daily volume of 40,305,247 shares, the days-to-cover ratio is presently 0.0 days. Based on an average daily volume of 40,305,247 shares, the days-to-cover ratio is presently 0.0 days. Currently, 15.0% of the company’s shares are sold short.

INVO Fertility Price Performance

INVO Fertility stock traded up $0.01 during trading hours on Tuesday, reaching $1.11. The stock had a trading volume of 594,178 shares, compared to its average volume of 20,746,982. The stock has a market cap of $2.65 million, a PE ratio of 0.00 and a beta of 2.65. The company has a fifty day simple moving average of $1.16 and a 200-day simple moving average of $5.19. INVO Fertility has a 52 week low of $0.71 and a 52 week high of $123.52.

Analysts Set New Price Targets

Separately, Maxim Group set a $4.00 price objective on INVO Fertility in a research note on Tuesday. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell” and an average price target of $4.00.

Institutional Investors Weigh In On INVO Fertility

A hedge fund recently bought a new stake in INVO Fertility stock. Citadel Advisors LLC acquired a new position in INVO Fertility, Inc (NASDAQ:IVF) during the third quarter, according to its most recent filing with the SEC. The firm acquired 66,849 shares of the company’s stock, valued at approximately $51,000. Citadel Advisors LLC owned about 1.19% of INVO Fertility as of its most recent filing with the SEC. Institutional investors and hedge funds own 12.02% of the company’s stock.

About INVO Fertility

INVO Fertility (NASDAQ:IVF) is a medical technology company focused on advancing assisted reproductive treatments through innovative in-vivo incubation solutions. The company develops and commercializes devices designed to facilitate fertilization and early embryo development inside a patient’s body, offering an alternative to conventional laboratory-based in vitro fertilization (IVF) techniques.

The company’s flagship product, the INVOcell device, is a single-use, intravaginal incubator that holds a controlled microenvironment for egg and sperm co-incubation.